Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
about
Multifunctional receptor-directed drugs for disorders of the central nervous systemAlterations of serum cholinesterase in patients with gastric cancerDopamine receptor 3 might be an essential molecule in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.Alzheimer's disease and age-related memory decline (preclinical)The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in ratsWhy do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agentsNovel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.Multifunctional drugs with different CNS targets for neuropsychiatric disorders.Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm).Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's disorders?Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.Rational drug discovery design approaches for treating Parkinson's disease.Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.
P2860
Q28305096-A8506366-3BC7-43F1-97D4-949D08609EF3Q28391893-D8E6B0A2-F0AF-421E-97C1-A06E8565B481Q34883582-86E9110A-565C-4137-ADEB-EC200A81F6FEQ35041190-DC6D670B-4203-4862-AF04-152191EC18FAQ35545032-EF83D05A-4404-4EFF-83E7-06FFF5B51DF0Q35546008-376C6AFE-75C6-4298-86F3-9888723D1A5BQ36349629-6EE509FC-C001-439B-BEBC-0324B41F8A6EQ36364388-13B6640E-157C-4F38-A0BD-B5C8DEA50CC8Q36543057-1DAF5C03-254E-4C24-96BC-8C1B2B8BA2A6Q36630021-B73D9754-C93E-4465-9F71-25CC39B9A6A1Q36633623-A9701571-DD3A-4504-9794-3693361B63D1Q36919155-FED31D35-22CF-4D2C-A5B0-88B2E0F24A8CQ37358680-1F3E3ADB-29CF-48D7-9CBC-04D0E72C1784Q38067297-0589F6CC-6160-45DC-B374-B69D44416DD5Q38447289-C36ED7EF-918C-4CF7-85B1-8536A8F167D3Q38520864-AA61C1BD-462B-43D2-B78E-549FE80E0657Q39694072-72476229-90C0-43F4-8428-C99EC2DF8319
P2860
Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Attenuation of MPTP-induced do ...... e-monoamine oxidase inhibitor.
@en
Attenuation of MPTP-induced do ...... e-monoamine oxidase inhibitor.
@nl
type
label
Attenuation of MPTP-induced do ...... e-monoamine oxidase inhibitor.
@en
Attenuation of MPTP-induced do ...... e-monoamine oxidase inhibitor.
@nl
prefLabel
Attenuation of MPTP-induced do ...... e-monoamine oxidase inhibitor.
@en
Attenuation of MPTP-induced do ...... e-monoamine oxidase inhibitor.
@nl
P2093
P2860
P1476
Attenuation of MPTP-induced do ...... e-monoamine oxidase inhibitor.
@en
P2093
Marta Weinstock
Moussa B H Youdim
Yotam Sagi
P2860
P304
P356
10.1046/J.1471-4159.2003.01801.X
P407
P577
2003-07-01T00:00:00Z